Table of Contents
Clinical Perspective on Citizen Petition
Clinical Perspective
Clinical Perspective
Clinical Perspective
Clinical Perspective
Clinical Perspective
Safety Presentation
Safety Presentation - Caveats
Safety Presentation - Caveats
NDA Data Introduction
NDA Safety Data
NDA Safety Data Introduction
NDA Safety Data Introduction
Claritin NDA Database
Claritin NDA Database
Claritin NDA Database
Claritin Cardiac Safety
Claritin Metabolic Considerations
Zyrtec NDA Database
Zyrtec NDA Database
Zyrtec NDA Database
Zyrtec Cardiac Safety
Zyrtec Metabolic Considerations
Allegra NDA Database
Allegra NDA Database
Allegra NDA Database
Allegra Cardiac Safety
Allegra Metabolic Considerations
NDA summary
POST-MARKETING
POST-MARKETING
POST-MARKETING - OTC antihistamines
POST-MARKETING – Claritin
POST-MARKETING – Claritin
POST-MARKETING – Claritin
POST-MARKETING – Zyrtec
POST-MARKETING – Zyrtec
POST-MARKETING – Zyrtec
POST-MARKETING – Zyrtec
POST-MARKETING – Allegra
POST-MARKETING – Allegra
POST-MARKETING – Allegra
POST-MARKETING
Epidemiology Assessment
Epidemiology Assessment
Epidemiology Assessment
Epidemiology Conclusions:
Overall Clinical/Regulatory Conclusions
Overall Conclusions
Overall Conclusions
Advice Sought from NDAC/PADAC
|